Early research (Phase 1)Study completedNCT02675478What this trial is testingPhase 1 Study of QuizartinibWho this might be right forRelapsed AMLRefractory AML Daiichi Sankyo Co., Ltd. 17
Testing effectiveness (Phase 2)Study completedNCT00053287What this trial is testingFludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDSWho this might be right forLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases Case Comprehensive Cancer Center 42
Testing effectiveness (Phase 2)Study completedNCT04173585What this trial is testingTEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With BortezomibWho this might be right forAcute Myeloid Leukemia University Hospital Heidelberg 50
Early research (Phase 1)Looking for participantsNCT06552416What this trial is testingSafety of MT-401-OTS in Patients With Relapsed AML or MDSWho this might be right forAcute Myeloid Leukemia, in RelapseMDS Marker Therapeutics, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT00245037What this trial is testingBusulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerWho this might be right forChronic Myeloproliferative DisordersLeukemiaLymphoma+4 more OHSU Knight Cancer Institute 147
Testing effectiveness (Phase 2)Study completedNCT01126814What this trial is testingImatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid LeukemiaWho this might be right forLeukemia University Health Network, Toronto 35
Early research (Phase 1)Ended earlyNCT02267863What this trial is testingAPTO-253 in Patients With Relapsed or Refractory AML or MDSWho this might be right forAcute Myelogenous Leukemia in RelapseAcute Myelogenous Leukemia, Relapsed, AdultAcute Myelogenous Leukemia, Adult+2 more Aptose Biosciences Inc. 21
Testing effectiveness (Phase 2)WithdrawnNCT03207334What this trial is testingICare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)Who this might be right forAcute Myeloid Leukemia University of Florida
Not applicableEnded earlyNCT01077440What this trial is testingPresence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell TransplantWho this might be right forCancer SurvivorChronic Myeloproliferative DisordersLeukemia+6 more Vanderbilt University 24
Not applicableEnded earlyNCT00255684What this trial is testingFludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic CancerWho this might be right forChronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more University of Rochester 16
Testing effectiveness (Phase 2)Study completedNCT00003340What this trial is testingCyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous LeukemiaWho this might be right forLeukemia Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Ended earlyNCT00555048What this trial is testingAlemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWho this might be right forGraft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes+1 more Fred Hutchinson Cancer Center 1
Early research (Phase 1)Ended earlyNCT02635074What this trial is testingIbrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forRecurrent Adult Acute Myeloid Leukemia Steven E. Coutre 2
Early research (Phase 1)UnknownNCT03825146What this trial is testingThe Effects of AMPC in the Treatments of Refractory or Relapsed AMLWho this might be right forAcute Myeloid Leukaemia Recurrent Lai Corporation Pty. Ltd. 10
Early research (Phase 1)Study completedNCT01174888What this trial is testingPhase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia FollowingMyelodysplastic Syndrome+8 more Alison Walker 34
Post-approval studies (Phase 4)UnknownNCT00196768What this trial is testingTreatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With ArsenicWho this might be right forRelapsed Acute Promyelocytic LeukemiaRefractory Acute Promyelocytic Leukemia German AML Cooperative Group 30
Testing effectiveness (Phase 2)Study completedNCT02044796What this trial is testingFilgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesWho this might be right forAcute Biphenotypic Leukemiade Novo Myelodysplastic SyndromePreviously Treated Myelodysplastic Syndrome+3 more Fred Hutchinson Cancer Center 199
Early research (Phase 1)Study completedNCT03661515What this trial is testingSelinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLWho this might be right forAcute Myeloid Leukemia PETHEMA Foundation 16
Early research (Phase 1)Study completedNCT01684150What this trial is testingA Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias InvolvingWho this might be right forAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome+1 more Epizyme, Inc. 51
Early research (Phase 1)Study completedNCT03207191What this trial is testingTrial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationWho this might be right forAcute Myeloid Leukemia (AML) Relapse Philogen S.p.A. 15